Xemed hosts Scientific Advisory Committee meeting

Xemed announced that it hosted a meeting of its Scientific Advisory Committee in Durham, New Hampshire. The 2010 visiting committee consists of Sean B. Fain, PhD, Associate Professor at the University of Wisconsin School of Medicine and Public Health and Talissa A. Altes, MD, Associate Professor of Radiology, Section Head of Pediatric Radiology, and Chair of Clinical Research at the University of Virginia Health System. Xemed CEO, Bill Hersman opened the meeting by presenting his vision of Xemed’s strategic opportunities, strengths, and challenges. New capabilities and technological milestones were presented by each of Xemed’s Division Heads, including Jan Distelbrink, PhD, Director of MagniXene™ Polarization Systems, David Watt, PhD, Director of MagniLium Polarization Systems, and Iulian Ruset, PhD, Director of Imaging Applications. Isabel Dregely, a newly minted PhD at the University of New Hampshire, presented new data acquired with Xemed’s polarizing technology. A tour of facilities was led by Walter Porter, Director of Engineering and Production, and Stephen Ketel, Clinical Research Associate. A photograph was taken that included the visiting committee, Xemed staff, student interns, and Xemed’s newly assembled xenon polarizer, the XeBox-E10 MagniXene™ production system. Dr. Hersman concluded the formal presentations with Xemed’s outline of plans and projections. A closed session of discussion and feedback followed.

Back row standing: Bill Hersman, Sean Fain, Dave Watt, Tally Altes, Iulian Ruset, Jeff Ketel, Isabel Dregely, Jan Distelbrink <br/>Middle kneeling: Walt Porter, Jeff Ortakales<br /> Front row: Steve Bryn, Steve, Ketel, Christina Johnson, Aaron Hope

ABOUT XEMED—We are a product-focused diagnostic drug company with broad expertise and IP in the field of hyperpolarized gases, partnering with clinical researchers and the pharmaceutical industry to advance pulmonary functional MRI through regulatory approval towards worldwide commercial availability.

At Xemed, our mission is to develop inhaled diagnostic agents that are capable of improving the standard of care of respiratory diseases. We will accomplish this by establishing hyperpolarized gas as a scientifically robust, clinically validated, FDA approved, and publically available diagnostic agent for magnetic resonance imaging of lung functional microstructure. We work to demonstrate effectiveness in two fields: 1) guiding clinical management of respiratory diseases, and 2) as a drug development tool to evaluate of the safety and efficacy of new therapies